Clin2
NCT06352307Worth exploringRecruiting

Prevention and treatment strategies for arrhythmogenic cardiomyopathy

Arrhythmogenic Cardiomyopathy

Part of Heart & circulation clinical trials.

This trial evaluates early prevention and treatment strategies for arrhythmogenic cardiomyopathy (ACM), a heart condition that can cause abnormal heart rhythms. It aims to improve care by using advanced tests like heart imaging and genetic sequencing to guide treatment.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
1,500 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 years or older.
  • You have been diagnosed with arrhythmogenic cardiomyopathy (ACM) using heart ultrasound, ECG, MRI, biopsy, or genetic testing.
  • You or your family agree to join the study and sign a consent form.
  • Your medical records are complete enough for the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05569356Not yet recruiting
Study of heart muscle disease causes, outlook, and tests

This study looks at how arrhythmogenic cardiomyopathy develops, how doctors can better diagnose it, and what it may mean for a person’s future risk. Because the study focuses on people with known genetic causes, it may help improve understanding for patients and families with this condition.

Paris
NCT06976606Recruiting
A study of adults with PKP2-linked arrhythmogenic cardiomyopathy

This study follows people with a confirmed PKP2 genetic mutation and arrhythmogenic cardiomyopathy (ACM) to understand how their condition changes over time. It may help doctors learn more about the disease and plan future treatments.

Redwood City, California
NCT06174220Recruiting· Phase 2
Tideglusib for genetic arrhythmogenic cardiomyopathy

This trial tests a medication called tideglusib to see if it can reduce extra heartbeats in people with a genetic form of arrhythmogenic cardiomyopathy. It may help stabilize the heart's rhythm and slow disease progression.

Calgary, Alberta
NCT06922994Recruiting· Phase 2
Testing atorvastatin for arrhythmogenic cardiomyopathy

This trial tests if a common cholesterol medicine, atorvastatin, can slow the progression of arrhythmogenic cardiomyopathy, a genetic heart condition that can cause abnormal heart rhythms. If you have this condition, joining this study may help researchers find a new way to protect your heart.

Pavia, PV
NCT06352320Recruiting
Improving care for cardiomyopathy patients

This trial aims to better understand and treat cardiomyopathy by studying patients' hearts with advanced tests. It seeks to find new ways to prevent or manage the condition early.

Xi'an, Shaanxi
NCT07708311Not yet recruiting
Cardiac rehab for people with high genetic risk of arrhythmogenic cardiomyopathy

This study tests a cardiac rehabilitation program designed for people with a high genetic risk of arrhythmogenic cardiomyopathy (a condition that affects the heart's rhythm and structure). It aims to see if a safe, supervised exercise plan can help improve heart function and quality of life.

Hear when a new Arrhythmogenic Cardiomyopathy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.